Your SlideShare is downloading. ×
Fda warns against healthy life chemistry by purity
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Fda warns against healthy life chemistry by purity

1,941

Published on

FDA warns the consumers not to use Healthy life chemistry by purity first B-50 which contains hidden ingredients like Methasterone and Dimethazine.

FDA warns the consumers not to use Healthy life chemistry by purity first B-50 which contains hidden ingredients like Methasterone and Dimethazine.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,941
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. FDA warns against Healthy Life Chemistry By Purity First B-50 P.Naina Mohamed Pharmacologist
  • 2. Introduction  FDA is warning consumers that they should not use or purchase Healthy Life Chemistry By Purity First B-50, marketed as a vitamin B dietary supplement.  A preliminary FDA laboratory analysis indicated that the product contains two potentially harmful anabolic steroids—methasterone, a controlled substance, and dimethazine.  These ingredients are not listed in the label and should not be in a dietary supplement.
  • 3. Methasterone  Methasterone is an anabolic steroid used as muscle-enhancing and body-building supplement and is a controlled substance. Mathasterone Analogue of Testosterone Slower metabolism Higher plasma level Mimic the anabolic action of Testosterone Increased muscle mass
  • 4. Hepatotoxicity Methasterone Increase oxidative stress Impairment of canalicular bile salt export pump Irregulation of bile production Cholestasis, Jaundice
  • 5. Cerebrovascular disease Methasterone May suppress prostacyclin production in arterial smooth muscle Increased risk of thrombin formation Cerebral infarction
  • 6. Cardiovascular disease Chronic use of Methasterone Increased triglyceride lipase activity Reduction of HDL and elevation of LDL Increased risk of cardiovascular disease
  • 7. Coronary Vasospasm Methasterone Inhibition of Guanylyl transferase enzyme Reduced synthesis of cGMP Inhibition of nitric oxide induced caronary vasodilation Coronary vasospasm
  • 8. Gynecomastia Chronic use of Methasterone Induce Aromatase CYP19 enzyme Conversion of testosterone to estradiol Estradiol binds to estrogen receptor Gynecomastia
  • 9. Dimethazine  Dimethazine contains two Methasterone molecules bound together by a nitrogen atom.  Dimethazine is less anabolic and more androgenic than Superdrol.  Dimethazine can not convert to estrogen and is free from estrogenic side effects.  It is fairly androgenic so androgenic side effects such as hair loss are a possibility with Dimethazine.  Dimethazine is dimethylated, so it does put significant stress on the liver.  A common side effect experienced with Dimethazine is painful muscle pumps/cramps, especially in the lower back and calves.
  • 10. Conclusion  Health care professionals are advised to ask their patients about any dietary supplements they may be using, particularly in patients exhibiting warning signs that may be associated with the use of steroids or steroid-like substances.  These warning signs include liver injury, kidney failure and stroke. They also include hormone-associated adverse effects such as blood clots, including pulmonary embolism (a sudden blockage in a lung artery), and deep vein thrombosis (a blood clot that forms in a vein deep in the body, often in the lower leg or thigh).  Consumers using Healthy Life Chemistry By Purity First B-50 who experience symptoms should consult a health care professional and report their experience to the FDA.
  • 11. References  http://www.fda.gov/Safety/MedWatch/SafetyInformat ion/SafetyAlertsforHumanMedicalProducts/ucm3628 00.htm?source=govdelivery  https://www.clinicalkey.com/#!/ContentPlayerCtrl/do PlayContent/1-s2.0-S1542356507011068  http://www.ncbi.nlm.nih.gov/pubmed/18563865.1  https://www.clinicalkey.com/#!/ContentPlayerCtrl/do PlayContent/1-s2.0-S1052305711002205  https://www.clinicalkey.com/#!/ContentPlayerCtrl/do PlayContent/1-s2.0-S0011502913000631

×